<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01304992</url>
  </required_header>
  <id_info>
    <org_study_id>LSEP H48-11</org_study_id>
    <nct_id>NCT01304992</nct_id>
  </id_info>
  <brief_title>Cholesterol-lowering Effects of Lupin Protein</brief_title>
  <official_title>Effects of Lupin Protein on Lipid and Protein Metabolism in Moderate Hypercholesterolemic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Jena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Jena</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to determine the efficacy of lupin protein drinks (Lupinus
      angustifolius Boregine) in humans. Parameters concerning cardiovascular risk factors and the
      metabolism of proteins, lipids and cholesterol will be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on the preliminary finding that a daily dosage of 35 g lupin protein is capable to
      affect plasma lipids positively, the physiological effects of two different daily lupin
      protein dosages will be investigated in two separate study groups (group A: 25 g protein/day;
      group B: 40 g protein/day). Both study groups undergo double-blinded and controlled study
      conditions in a cross-over design.

      In each of the two study groups 35 volunteers with hypercholesterolemia will be allocated to
      one of two randomization groups: After a 1-week run-in period (baseline), half of the 35
      participants of each study group will consume drinks with lupin protein in the respective
      amount (25 g or 40 g protein/day) over a period of eight weeks, the other half will receive
      the analogue amount of milk protein as well incorporated in a drink serving as control. After
      a wash-out period of four weeks, the protein source will be crossed within the two study
      groups for a second intervention period of eight weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cholesterol metabolism</measure>
    <time_frame>After 0, 4, 8, 12, 16 and 20 weeks</time_frame>
    <description>Blood lipids (LDL cholesterol, total cholesterol, HDL cholesterol, triacylglyceroles)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Protein metabolism</measure>
    <time_frame>After 0, 8, 12 and 20 weeks</time_frame>
    <description>Plasma: amino acids, total protein, albumin, urea, uric acid; Urine: total protein, ammonia, urea, uric acid; Proteomic-study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition (body status)</measure>
    <time_frame>After 0, 8, 12 and 20 weeks</time_frame>
    <description>Bioelectrical impedance analysis, body weight, blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-sensitive CRP</measure>
    <time_frame>After 0, 8, 12 and 20 weeks</time_frame>
    <description>As inflammation marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>After 0, 8, 12 and 20 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Lupin Protein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lupin protein (cultivar: Lupinus angustifolius Boregine; incorporated in a drink)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference protein</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reference Protein (75% sodium caseinate (EM7; DMV international) and 25% milk protein (Megglosat HP; Meggle), incorporated in a drink)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wash out</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Wash out (four weeks without any intervention between interventional periods)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Protein drink - low dosage</intervention_name>
    <description>The subjects will consume 500 mL of a protein drink containing 25 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.</description>
    <arm_group_label>Lupin Protein</arm_group_label>
    <arm_group_label>Reference protein</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Protein drink - high dosage</intervention_name>
    <description>The subjects will consume 500 mL of a protein drink containing 40 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.</description>
    <arm_group_label>Lupin Protein</arm_group_label>
    <arm_group_label>Reference protein</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate hypercholesterolemia (total cholesterol &gt;5,2 mmol/L)

          -  Age: 18-80 years old

        Exclusion Criteria:

          -  Intake of lipid-lowering pharmaceuticals

          -  Allergy against legumes or milk protein

          -  Intolerance against milk

          -  Pregnancy, lactation

          -  Chronic bowel disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerhard Jahreis, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friedrich Schiller University Jena, Institute of Nutrition, Department of Nutritional Physiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Friedrich Schiller University Jena, Department of Nutritional Physiology</name>
      <address>
        <city>Jena</city>
        <state>Thuringia</state>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2011</study_first_submitted>
  <study_first_submitted_qc>February 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2011</study_first_posted>
  <last_update_submitted>November 22, 2012</last_update_submitted>
  <last_update_submitted_qc>November 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Jena</investigator_affiliation>
    <investigator_full_name>Gerhard Jahreis</investigator_full_name>
    <investigator_title>Prof. Dr. habil.</investigator_title>
  </responsible_party>
  <keyword>Dietary protein</keyword>
  <keyword>Lupin protein</keyword>
  <keyword>Cholesterol metabolism</keyword>
  <keyword>Protein metabolism</keyword>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>Protein-enriched drinks</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

